Axsome Therapeutics (AXSM) Share-based Compensation (2022 - 2026)
Axsome Therapeutics' Share-based Compensation history spans 5 years, with the latest figure at $23.4 million for Q1 2026.
- On a quarterly basis, Share-based Compensation rose 0.56% to $23.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $93.9 million, a 6.28% increase, with the full-year FY2025 number at $93.8 million, up 10.01% from a year prior.
- Share-based Compensation hit $23.4 million in Q1 2026 for Axsome Therapeutics, up from $22.7 million in the prior quarter.
- Over the last five years, Share-based Compensation for AXSM hit a ceiling of $37.7 million in Q4 2022 and a floor of $7598.0 in Q1 2022.
- Historically, Share-based Compensation has averaged $17.9 million across 5 years, with a median of $21.4 million in 2024.
- The widest YoY moves for Share-based Compensation: up 177871.08% in 2023, down 49.83% in 2023.
- Tracing AXSM's Share-based Compensation over 5 years: stood at $37.7 million in 2022, then crashed by 49.83% to $18.9 million in 2023, then increased by 16.24% to $22.0 million in 2024, then grew by 3.38% to $22.7 million in 2025, then increased by 3.11% to $23.4 million in 2026.
- Business Quant data shows Share-based Compensation for AXSM at $23.4 million in Q1 2026, $22.7 million in Q4 2025, and $23.1 million in Q3 2025.